NDRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ENDRA Life Sciences Inc (NDRA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are mixed to negative, with no strong bullish signals. The company's financial performance is weak, showing significant declines in net income and EPS. Additionally, there are no positive news catalysts, no recent congress trading data, and no significant trading trends from insiders or hedge funds. Given the lack of positive momentum and the high likelihood of further price declines in the short and medium term, this stock does not align with the user's investment goals.
The MACD is negative and expanding downward, indicating bearish momentum. The RSI is neutral at 43.549, showing no clear signal. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading near its support levels (S1: 4.845), with a pivot at 5.589, suggesting limited upside potential. Historical candlestick patterns indicate a 40% chance of a slight 0.21% gain in the next day but a -2.47% decline in the next week and a -14.41% decline in the next month.
NULL identified. No recent news or significant trading trends from insiders or hedge funds.
Weak financial performance, with declining net income (-23.62% YoY) and EPS (-62.94% YoY). No positive news or trading sentiment. Historical patterns suggest a high probability of price declines in the short and medium term.
In Q4 2025, the company's revenue remained at 0 with no growth. Net income dropped to -$3,169,209, down -23.62% YoY. EPS fell to -2.85, a significant -62.94% YoY decline. Gross margin remained at 0 with no improvement.
No analyst rating or price target changes available.
